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Introduction: Minor ABO mismatch occurs when donors possess
pre-existing immunity to recipient ABO antigens. This combination
presents a risk for clonal expansion of donor B lymphocytes targeting
discrepant ABO antigens after allogeneic hematopoietic cell
transplantation (HCT).
Material and Methods: 1594 patients underwent allo-HCT be-
tween January 1986 and June 2010. Recipient age ranged 0-74 (me-
dian 40) years. 47% underwent allo-HCT for acute leukemia, 13%
for NHL/CLL. 72% received myeloablation, while 28% underwent
reduced-intensity conditioning (RIC). Recipient-donor pairs were
61% ABO matched 18% major mismatched (mm), 17% minor
mm, and 4.5% bidirectional mm. 45% of grafts derived from bone
marrow (BM), 55% from peripheral blood (PB). ABO mm distribu-
tion did not differ by age, disease, conditioning, or graft source.
Median follow-up was 5.7 years.
Results: Compared to ABO matched HCT, OS was inferior across
allminormmpairs (medianOS 2 years vs 7.4 years for ABOmatched,
p\0.0001;CoxHR1.3, 95%CI1.1-1.8, p50.003).Minormmpairs
were found to have significantly increased NRM through day 100
(18% vs 13%, p 5 0.02; HR 1.5, 95%CI 1.06-2.05, p 5 0.02). Im-
paired OS predominated in minor mm receiving BM (HR 1.8, 95%
CI 1.3-2.3, p\ 0.0001) compared with PB grafts (HR 1.1, 95%CI
0.8-1.4, p5 0.59). Interestingly, patients transplanted for acute leu-
kemia exhibited the survival impairment (HR 1.3, 95%CI 1.1-1.6, p
5 0.01) whereas those allografted for NHL/CLL did not (HR 1.1,
95%CI 0.6-1.8, p 5 0.8). OS and NRM differences in the minor
mmpairs did not correlate with conditioning regimen or donor relat-
edness. A trend toward increased acute GVHD was observed in mi-
nor mm recipients (HR 1.3, 95%CI 1.0-1.7; p 5 0.08). Since 2005,
replacement of graft plasma has not ameliorated inferior outcomes
in minor mm HCT, suggesting a cellular etiology. Major mm pairs
did not demonstrate impairments in OS or differences in NRM.
Conclusion: Minor ABO mismatch between recipients and donors
is associated with significantly impaired OS and increased NRM fol-
lowing allo-HCT and should be avoided if possible. In particular,
minor mm BM grafts have inferior outcomes, and we hypothesize
the survival deficit is attributable to increased ABO reactive B cell
content in BM compared with PB. The abrogation of survival im-
pairment in minormmNHLpatients may result from peritransplant
use of Rituximab leading to in vivo depletion of these pathogenic
ABO reactive B cells.365
A PILOT STUDY OF T-CELL DEPLETED ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION WITH BUSULFAN, MELPHALAN, AND
FLUDARABINE CONDITIONING FOLLOWED BY POST TRANSPLANTATION
DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS WITH RELAPSED
MULTIPLE MYELOMA AND HIGH-RISK CYTOGENETICS
Koehne, G.1, Landau, H.1, Hassoun, H.2, Lesokhin, A.2, Lendvai, N.2,
Rosenzweig, M.1, Chung, D.J.2, Young, J.W.1, Giralt, S.1 1Adult Bone
Marrow Transplantation Service; 2Memorial Sloan-Kettering Cancer
Center, New York, NY
Allogeneic hematopoietic stem cell transplantation (allo HSCT) is
a curative therapy for patients (pts)withmultiplemyeloma,but conven-
tional allo HSCT has been associated with unacceptably high rates of
mortality. Non-myeloablative allo HSCT has resulted in high rates
of acute and chronic graft-versus-host disease (GvHD) and progres-
sion.We report initial results of a pilot study of 13 pts, usingT-cell de-
pleted alloHSCT (alloTCDHSCT) fromHLA compatible (matched
related8, matched unrelated3, andmismatched unrelated2) donors. All
13 pts had relapsedmyelomawithin 12mos following autoHSCT, and
12/13 pts had high-risk cytogenetics at diagnosis [t(4;14), t(14;16),
del17p byFISHand/or del13qby karyotyping]. All pts achieved at least
a partial response from preceding chemotherapy or second auto
HSCT. Pts underwent allo TCD HSCT with busulfan (0.8mg/kg x
10 doses), melphalan (70mg/m2 x 2 days), fludarabine (25mg/m2 x 5
days) and rabbit ATG (2.5mg/kg x 2 days). T-cell depletion was per-
formed by positive CD34 selection (Isolex) followed by rosetting
with sheep erythrocytes, achieving\ 103CD3+/kg for all grafts. Allpts engrafted promptly (median d+11, range d+10 to +12). Pts were el-
igible toreceive lowdosesofdonor lymphocyte infusions (DLI) (5x10e5
– 1x10e6 CD3+/kg) no earlier than 5mos post alloHSCT. Five pts are
in continuous complete remission (CR) at 28, 22, 12, 10 and 9mos fol-
lowing allo TCD HSCT. Two of these pts reentered CR following
DLI.Twoptshad stableminimal residual disease for 26 and24mosbe-
fore progression and are being treated with DLI at the current time.
Twopts with refractorymyeloma,whowere transplantedwith residual
16%and10%plasmacells inmarrow,were inCR for 12and8mospost
allo TCD HSCT, developed progression of disease and recently re-
ceivedDLI. 12/13ptswerewithout signsofGvHD,but onepthadpos-
sible superimposed gut GvHD following fulminant C diff colitis. Four
pts died, incl one at 2 mos with oseltamivir-resistant H1N1 infection;
one at 4 mos due to respiratory failure secondary to infection of un-
known etiology, one at 5 mos due to status epilepticus, and one at 6
mos due to acute cerebral hemorrhage.
We are now performing a phase II clinical trial at MSKCC for pts
with relapsed multiple myeloma following auto SCT who had high-
risk cytogenetics at diagnosis or at relapse as well as upfront allo
HSCT for pts with high-risk cytogenetics at diagnosis following
preceding auto SCT.366
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We evaluated a photodepletion technique to selectively deplete
graft-versus-host disease (GVHD) alloreacting T cells from stem cell
transplants. Donor lymphocytes were stimulated with irradiated in-
vitro expanded recipientT lymphocytes.AlloactivatedTcells preferen-
tially retaining the photosensitizer 4, 5-dibromorhodamine 123
(TH9402) (Kiadis Pharma, NL) were eliminated by light exposure.
Twenty-four patients with hematological malignancies (16 high-risk)
conditioned with fludarabine, cyclophosphamide and total body,
irradiation received a CD34-selected stem cell allograft from an HLA
identical sibling and 5x106/kg selectively depleted (SD) donor T cells.
Low-dose cyclosporine was used as the only post-transplant immuno-
suppression. The overall probability of grade III-IV a-GVHD was
13%. Fourteen patients developed chronic GVHD (c-GVHD). Five
patients relapsed, 2 of whom remain alive in remission after further
treatment. Thirteen patients survive at a median of 22months. Overall
survival and disease free survival probabilities (+/2 SEM) were 43 +/2
13%and 35 +/2 13% respectively. TheSD technique resulted in a low
incidence of relapse (24 +/2 10%), butwas complicated by late non-re-
lapsemortality associated with c-GVHD and infection of 50 +/2 14%
at 4 years follow up. These results suggest that SD may effectively re-
duce severe a-GVHD while conserving graft-versus leukemia effects,
but the depletion strategy has yet to be optimized.367
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Double unit cord blood transplantation (DCBT) is a frequent
strategy to augment graft cell dose. However, in the majority of
Poster Session II S287patients, donor hematopoiesis is accounted for by one unit, although
the mechanisms of unit dominance are not established. Cord blood
NK cells are predominantly of a mature phenotype, with cytotoxic
activity following IL-2 stimulation comparable to peripheral blood
NK cells, but with higher proliferation capacity. We, therefore, hy-
pothesized that NK cells may determine unit dominance following
DCBT. We examined KIR haplotypes of each unit, and the unit-
unit and unit-recipient KIR-HLA interactions in 83 DCBT recipi-
ents transplanted at MSKCC between October 2005 and July 2010
for hematological malignancies. Median age of patients was 35.6
years (0.9-64.6). Patients received myeloablative (n 5 65) or non-
myeloablative (n 5 18) conditioning, and immunosuppression with
a calcineurin inhibitor and mycophenolate mofetil. Chi-square test
was used to examine the frequency distributions differences of spe-
cific KIR haplotypes and individual activating KIR between the pre-
dominating and the non-engrafting units. It was also used to test
equal frequency distributions of inhibitory KIR-mediatedmissing li-
gand ormissing self. Group B-haplotypes (34.9% vs. 41.4%, p5 0.2)
were not associated with a higher likelihood of unit dominance. Sim-
ilarly, none of the individual activating KIR showed any association
with unit dominance. The majority of unit pairs either had no KIR-
HLA combinations predictive of NK alloreactivity (n 5 20), or had
NK alloreactivity predicted to occur in a bidirectional manner (n 5
35). Results from unit-unit interaction analyses showed that units
missing KIR ligand (16/29 vs 13/29, p5 0.71), or lacking class I de-
terminants present in the second unit (12/18 vs 6/18, p 5 0.23), did
not show a lower rate of engraftment. For unit-recipient interac-
tions, cord blood units did not have a higher likelihood of engraft-
ment even if the patient was missing ligand for the unit inhibitory
KIR (2/7 vs. 5/7, p 5 0.45), or lacked class I determinants present
in the unit (7/16 vs. 9/16 p 5 0.80). Results from recipient-unit in-
teraction analyses revealed that units missing KIR ligand (12/25 vs.
13/25, p5 1.00) or lacking class I determinants present in the recip-
ient (9/19 vs. 10/19, p 5 1.00) did not show a lower rate of engraft-
ment. In this cohort of DUCBT, we could not demonstrate a role for
KIR-HLA genotypes or KIR haplotypes in predicting cord unit
predominance.368
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Allogeneic hematopoietic stem cell transplantation(HSCT) must
serve as a platform for adoptive cellular immunotherapy to fully ex-
ploit graft versus leukemia effects. We have developed a 4-log ex-
vivo T lymphocyte depleted HSCT with minimal graft versus host
disease (GvHD) prophylaxis followed by elective donor lymphocyte
infusion at day 90. A lymphodepleted environmentwithout immuno-
suppressionwould favor homeostatic expansion of adoptively infused
cells in future protocols. 39 patients with hematologic malignancies
underwent allogeneic HSCT with a graft from their HLA-identical
siblings. The median age was 41 years (range 16-68), 17/39 were
males. Transplant indications were AML(18), ALL(8), acute biphe-
notypic leukemia(1), MDS(7), NHL/CLL(3), CMMoL(1) and
CML(1). 50% were standard risk and 50% were at high risk for re-
lapse. Subjects received myeloablative conditioning with cyclophos-
phamide (60 mg/kg/dose x 2), fludarabine (25 mg/m2/dose x 5) and
total body irradiation (12 Gy in 8 fractions, lungs shielded to 6Gy).
Ten subjects,whowere 55 years of age or older, received 4Gydivided
in 8 fractions without lung shielding. G-CSF mobilized peripheral
blood grafts from the donor were CD34+ selected (Miltenyi Clini-
Macs), with infusion of a target CD34+ dose of 6x10e6/kg and a fixed
CD3+ dose of 5x10e4/kg. Low-dose cyclosporine (100-200ng/mL)
till day 21 was the only GVHD prophylaxis. Delayed lymphocyte
add back (5x10e6CD3+/kg) was given at day 90 if patients had no sig-
nificant GVHD. CD3+ and myeloid chimerism analyses were per-
formed with early lymphocyte add-back in cases with fallingchimerism. Day 200 overall survival (the primary study endpoint)
was 84%. One patient, who was postpartum, failed to engraft and re-
quired a second transplant. 37/39 subjects achieved complete
(. 95%) donor myeloid chimerism by day14. The median times to
complete donor CD3+ chimerism were day30 for 12 Gy subjects
and . 6 months for 4 Gy subjects (Mann Whitney test, p 5 0.004).
The incidence of acute GVHD grade II, III and IV were 23%,
2.9% and 0%, respectively. The incidence of chronic GVHD was
34%. At a median follow up of 3.7 years, Kaplan-Meier estimates
of relapse, nonrelapse mortality and overall survival were 32%,
31% and 46% respectively without any significant difference based
on conditioning intensity. In conclusion, conditioning intensity in-
fluences the rapidity of complete donor CD3+ chimerism in trans-
plants utilizing this platform for adoptive cellular immunotherapy.369
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In leukemia patients, peripheral blood stem cells (PBSC) have re-
placed bone marrow (BM) as stem cell source. No study has shown
any benefit using PBSC versus BM in matched unrelated donor
(MUD) transplantation. We therefore compared PBSC and BM in
MUD recipients with acute myeloid leukemia (AML).
Between 1997 and 2008, 760 patients received BM and 1,502
PBSC from a MUD. The PBSC group were older age (p\ 0.01),
had more advanced disease (p\0.0001), received less total body ir-
radiation (p\0.0001), and more antithymocyte globulin (p5 0.01).
Recovery of neutrophils and platelets was faster with PBSC (p\
0.0001). Acute GVHD was similar, but chronic GVHD was in-
creased in the PBSC group (HR 1.29, p 5 0.02). Non-relapse mor-
tality (NRM), relapse and leukemia-free survival (LFS) did not differ
between the two groups, in AML patients in remission. However, in
patients with advanced AML, NRM was decreased (HR 0.61, p 5
0.02) and LFS was improved (HR 1.49, p 5 0.002) using PBSC.
At 3 years, LFS for all patients, regardless of remission status, was
4161% for both groups.
PBSC compared to BM in MUD transplants in AML resulted in:
faster neutrophil and platelet recovery, not statistically different
acute GVHD, increased chronic GVHD and same rates of LFS in
remission patients. In advanced AML, the PBSC group had
decreased NRM and improved LFS.370
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Achieving engraftment of T cell depleted BMT under reduced in-
tensity conditioning (RIC) remains a major challenge. Recently, we
demonstrated that anti 3rd-party CD8 T cells with ex-vivo induced
central memory phenotype (Tcm) can enhance BM engraftment
